Jobs

Currently 45 Pharmacy jobs

Candidates Login

CV Database

Let the jobs come to you!

Company Login

Site Newsletter

Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

PharmiWeb on Facebook

Advertising

Press Releases

submit a press release

168 Press Releases

1 2 3 4 5 6

Date	Title	Company
11 Apr 13	Biogen Idec to Report First Quarter 2013 Financial Results on April 25, 2013	Biogen Idec Inc., Published by Business Wire
03 Apr 13	Biogen Idec Completes Purchase of Full Rights and Control of TYSABRI®	Biogen Idec, Published by Business Wire
20 Mar 13	Positive Year One Results from Biogen Idec Phase 3 ADVANCE Trial of PLEGRIDY™ (Peginterferon Beta-1a) Presented at AAN Meeting	Biogen Idec, Published by Business Wire
20 Mar 13	US Patent Office Grants Patent Claiming Dosing Regimen for TECFIDERA™ (Dimethyl Fumarate)	Biogen Idec, Published by Business Wire
12 Mar 13	Biogen Idec Submits Application to FDA for First Long-Lasting Factor VIII Therapy for Hemophilia A	Biogen Idec, Published by Business Wire
04 Mar 13	FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor IX Therapy for Hemophilia B	Biogen Idec, Published by Business Wire
28 Feb 13	Biogen Idec to Present at the Cowen and Company 33rd Annual Healthcare Conference	Biogen Idec Inc., Published by Business Wire
21 Feb 13	Biogen Idec to Present at the 2013 RBC Capital Markets Global Healthcare Conference	Biogen Idec Inc., Published by Business Wire
20 Feb 13	Biogen Idec to Present at the Citi 2013 Global Healthcare Conference	Biogen Idec Inc., Published by Business Wire
15 Feb 13	Cambridge Science Festival Announces Statewide Year-Round Science Outreach Initiative: Biogen Idec Foundation Science on the Street	Biogen Idec, Published by Business Wire
08 Feb 13	New Phase 3 Data Reinforce Long-Lasting Protection from Bleeding for Patients with Hemophilia A and B	Biogen Idec, Published by Business Wire
06 Feb 13	Biogen Idec to Acquire Full Rights and Control of TYSABRI® from Elan for Upfront Cash and Contingent Payments	Biogen Idec Inc., Published by Business Wire
28 Jan 13	Biogen Idec 2012 Revenue Increases 9% to $5.5 Billion	Biogen Idec Inc., Published by Business Wire
24 Jan 13	Biogen Idec Announces Positive Top-Line Results from Phase 3 Study of Peginterferon Beta-1a in Multiple Sclerosis	Biogen Idec, Published by Business Wire
16 Jan 13	Biogen Idec and Elan Submit Applications for First-Line Use of TYSABRI in anti-JCV Antibody Negative Patients with MS	Biogen Idec and Elan Corporation plc, Published by Business Wire
15 Jan 13	Biogen Idec to Report Fourth Quarter & Year End 2012 Financial Results on January 28, 2013	Biogen Idec Inc., Published by Business Wire
04 Jan 13	Biogen Idec Submits Application to FDA for First Long-Lasting Factor IX Therapy for Hemophilia B	Biogen Idec, Published by Business Wire
03 Jan 13	Biogen Idec Reports Top-Line Results from Phase 3 Trial Investigating Dexpramipexole in People with Amyotrophic Lateral Sclerosis (ALS)	Biogen Idec, Published by Business Wire
03 Jan 13	Biogen Idec to Present at the 31st Annual J.P. Morgan Healthcare Conference	Biogen Idec Inc., Published by Business Wire
12 Dec 12	Biogen Idec and Eisai Announce Manufacturing Alliance at Research Triangle Park Facilities	Biogen Idec, Published by Business Wire
30 Nov 12	Biogen Idec Opens New RTP Facility	Biogen Idec, Published by Business Wire
27 Nov 12	Biogen Idec to Present at the DB Access BioFEST Conference	Biogen Idec Inc., Published by Business Wire
08 Nov 12	Biogen Idec to Present at the Credit Suisse 2012 Annual Healthcare Conference	Biogen Idec Inc., Published by Business Wire
31 Oct 12	Biogen Idec and Sobi Announce Positive Top-Line Results from Phase 3 Study Investigating Long-Lasting Recombinant Factor VIII Fc Fusion Protein in Hemophilia A	Biogen Idec, Published by Business Wire
25 Oct 12	Biogen Idec Increases Revenue 6 percent to $1.4 Billion in the Third Quarter	Biogen Idec Inc., Published by Business Wire
18 Oct 12	Biogen Idec Receives Notification of PDUFA Date Extension	Biogen Idec, Published by Business Wire
12 Oct 12	New Data from Phase 3 Studies Provide Additional Evidence Supporting Treatment Effect for Oral BG-12 (Dimethyl Fumarate) in Multiple Sclerosis	Biogen Idec, Published by Business Wire
11 Oct 12	TYSABRI® (natalizumab) Data at ECTRIMS Reaffirm Positive Effects of Treatment for People with Relapsing Forms of MS	Biogen Idec and Elan Corporation plc, Published by Business Wire
10 Oct 12	Biogen Idec’s Commitment to MS Demonstrated Through Significant Scientific Data Being Presented at the 28th ECTRIMS	Biogen Idec, Published by Business Wire
05 Oct 12	Biogen Idec to Report Third Quarter 2012 Financial Results on October 25, 2012	Biogen Idec, Published by Business Wire

1 2 3 4 5 6

subscribe in a reader

Advertising

Share | | |

Site Map
Privacy & Security
Cookies
Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.